🔴 Moleculin Biotech is trading 10.72% down in pre-market

Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified.

• Its latest company announcement, on September 25, described preclinical Annamycin pancreatic-cancer findings presented at AACR.
• The company cautioned that preclinical results may not predict human outcomes; Annamycin is not in clinical development for pancreatic cancer.
• Broader sentiment was weaker, with Nasdaq futures down 0.88%, but available evidence does not establish this caused the decline. No volume or activity data is available.